These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Progression of renal disease--can it be reversed? The role of calcium channel blockers and angiotensin-converting enzyme inhibitors.
    Author: Boner G.
    Journal: Isr J Med Sci; 1996 Dec; 32(12):1217-21. PubMed ID: 9007157.
    Abstract:
    The treatment of patients with end-stage renal failure using dialysis has become an important factor in the health budgets of the developed countries. Thus, prevention of progression of renal disease and a reduction in the number of patients requiring dialysis should have a beneficial impact on health budgets. This review will examine the effects of calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACE-Is) on the progression of renal disease. Both CCBs and ACE-Is have been shown to slow progression in various animal models of various renal diseases. In the human with diabetic and non-diabetic renal disease, most CCBs have caused a stabilization of renal function and in some cases a decrease in proteinuria. ACE-Is have been effective in reducing proteinuria and stabilizing renal function in both diabetic and non-diabetic disease, this effect being independent of the antihypertensive effect. There are good theoretical reasons for using a combination of these two classes of medications, but there are still insufficient clinical data. In summary, both CCBs and ACE-Is may be used to slow the progression of renal disease. ACE-Is seem to be preferable, but there may be an advantage to the use of a combination of both agents.
    [Abstract] [Full Text] [Related] [New Search]